NE Oncology Issue – September 2014



  • Barbara Melosky, MD, FRCPC
  • British Columbia Cancer Agency, Vancouver, British Columbia


  • 52-year-old Caucasian female.
  • Cough for 4 months.
  • Abnormal chest X-ray showed a right middle lobe mass of 8 cm.
  • CT scan showed innumerable pulmonary nodules on both lungs.
  • PET scan showed disease: right lung lit up, multiple pulmonary nodules bilaterally lit up, and left adrenal gland lit up.
  • Patient has a history of light smoking: she smoked from 20 to 26 years of age, approximately 10 cigarettes per day.


Laboratory and Clinical Findings:


  • CBC and differential: normal
  • Liver function test: normal
  • CEA: high at 22 mcg/L


  • Decreased air entry to right base.
  • Performance status: 2
  • Bronchoscopy biopsy: adenocarcinoma (TTF positive)


  • Molecular mutation testing: ALK M–; EGFR M+ exon 19 deletion (Del19)


  • Stage 4 non-small cell adenocarcinoma of lung.
  • EGFR M+


  • Afatinib 40 mg/day (initial dose)
  • Patient is still on treatment 7 months later with no dose adjustments over that time period.


  • Clinical response within 3 weeks of starting afatinib, with improvement in cough.
  • Chest X-ray showed improvement by 4 weeks. PS improved to 1.
  • CT scan at 8 weeks showed partial response with reduction of mass in right lower lobe and disappearance of approximately 50% of pulmonary nodules.
  • Partial response continued to 7 months.
  • Treatment is ongoing.

AE Management:

  • Diarrhea (grade 2): Developed at 2 weeks.
  • Treated with Imodium® (loperamide).
  • Well controlled; used on and off for 7 months.
  • Mucositis (grade 2): Tingling of tongue and cracking of outside corners of lips at approximately 4 weeks.
  • Treated with Kenalog® (triamcinolone acetonide) in Orabase®(benzocaine) 0.1%.
  • Patient has used this very successfully and is using it on a periodic basis.
  • Skin rash (grade 1): Developed at 6 weeks.
  • Treated with topical steroid cream applied (hydrocortisone 1% with clindamycin 2%).
  • Patient has found this beneficial.
  • Pruritis (grade 1): Developed on fingertips at 6 months.
  • Treated with a high-dose steroid (betamethasone valerate) applied to nailbeds.
  • Patient has relief of symptoms.

melosky-fig2-lrg melosky-fig3-lrg melosky-fig4-lrg


  • Treatment with afatinib is ongoing in 52-year-old female with partial response and improvement in performance status (1) and QoL.

Abbreviations: ALK = anaplastic lymphoma kinase; CBC = complete blood count; CEA = carcinoembryonic antigen; CT = computerized tomography; EGFR = epidermal growth factor receptor; M+ = mutation-positive; M– = mutation-negative; PET = positron emission tomography; QoL = quality of life; TTF = thyroid transcription factor


Download Journal


Canadian Perspectives


Carolyn Owen, MD

Dr. Carolyn Owen completed postgraduate training in internal medicine and hematology at the University of Ottawa and the University of British Columbia, respectively, followed by a research fellowship in molecular genetics at Barts and the London School of Medicine and Dentistry in London, UK. Her research focused on familial myelodysplasia and acute myeloid leukemia. She is currently an Assistant Professor at the Foothills Medical Centre & Tom Baker Cancer Centre, and her clinical interests are low-grade lymphoma and chronic lymphocytic leukemia. She is also the local principal investigator in Calgary for several clinical trials in these areas.


David Macdonald, MD, FRCPC

Dr. David Macdonald is a hematologist at the QEII Health Sciences Centre in Halifax, Nova Scotia, and Assistant Professor in the Division of Hematology at Dalhousie University’s Faculty of Medicine. Dr. Macdonald chairs the Hematology Cancer Site Team for Cancer Care Nova Scotia. His interests are in hematologic malignancies and, in particular, lymphoproliferative disorders. He has done a Clinical Trials Fellowship with the National Cancer Institute of Canada – Clinical Trials Groups and is actively engaged in clinical trials research. Dr. Macdonald has also completed a clinical fellowship in the lymphoma group at the British Columbia Cancer Agency in Vancouver, and he maintains a clinical research program in lymphoma.


Jeffrey Rothenstein, MD, FRCPC

Dr. Jeffrey Rothenstein is a medical oncologist at the R.S. McLaughlin Durham Regional Cancer Centre in Oshawa and an Adjunct Assistant Professor in the Department of Oncology at Queen’s University in Kingston, Ontario. He completed his internal medicine and medical oncology training at the University of Toronto. Dr. Rothenstein’s main clinical focus is on the management of thoracic and gastrointestinal malignancies. He is the lung cancer site group leader at the R.S. McLaughlin Durham Regional Cancer Center.

Investigator Commentaries


Stephan Stilgenbauer, MD

Dr. Stephan Stilgenbauer is Associate Professor and Deputy Chairman at the Department of Internal Medicine III (Hematology, Oncology, Rheumatology and Infectious Diseases) at Ulm University, Germany. He received his medical training at Heidelberg Medical School and was trained in internal medicine and hematology-oncology at the Universities of Heidelberg and Ulm. He spent a postdoctoral fellowship at the German Cancer Research Center (DKFZ) in Heidelberg. His research focus is on the molecular pathogenesis of hematological malignancies and translation of this research into novel treatment strategies. Dr. Stilgenbauer has authored or co-authored numerous original articles, reviews, and book chapters in journals such as The New England Journal of Medicine, The Lancet, Nature Medicine, the Proceedings of the National Academy of Sciences of the United States of America, Journal of Clinical Oncology, Blood, Leukemia, Haematologica, among others.


C. Tom Kouroukis, MD

Dr. C. Tom Kouroukis graduated from the University of Toronto and completed training in Internal Medicine, Hematology and MSc (Health Research Methodology) training at McGill and McMaster Universities. He was awarded a National Cancer Institute of Canada Clinical Research Fellowship. He is a hematologist at the Juravinski Cancer Centre/Hamilton Health Science, Chair of the Hematology Disease Site Team, Head of the Division of Malignant Hematology, and Associate Professor in the Department of Oncology. He is Co-chair of the Hematology Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative and Chair of the Stem Cell Committee of Cancer Care Ontario. His research interests include the care of older patients with hematological cancers, the impact and evaluation of co-morbidity in older cancer patients, clinical trials, and practice guideline development.

Expert Commentaries

Laurie H. Sehn, MD, MPH
Dr. Laurie H. Sehn is a Clinical Assistant Professor at the BC Cancer Agency and the University of British Columbia in Vancouver. She has been a medical oncologist and clinical investigator with the Lymphoma Tumour Group since 1998. Dr. Sehn has served on the Board of Directors of Lymphoma Foundation Canada (LFC) since 2002 and is currently Director of Research Fellowships for the LFC. Dr. Sehn’s research interests include all of the lymphoid cancers, with particular interest in the biology and treatment of large-cell lymphoma, the application of new imaging techniques such as PET scanning to lymphoma management, and innovative new approaches to treatment.

Dietger Niederwieser, MD
Dr. Dietger Niederwieser is the Head of the Department of Hematology and Oncology at the University Hospital of Leipzig in Germany. He completed his medical degree and postgraduate training in internal medicine and hemato-oncology at the University of Innsbruck in Austria. His research interests include leukemia, myelodysplastic syndrome, renal cell carcinoma, Hodgkin lymphoma, allogeneic stem cell transplantation, and graft versus host disease and he is currently involved in a variety of clinical trials in these areas. Dr. Niederwieser is President of the Worldwide Network for Blood and Marrow Transplantation, past President of the European Group for Bone and Marrow Transplantation (EBMT), and a former Chair of the EBMT Chronic Leukemia Working Party. He is a member of several scientific societies, including the European Hematology Association, the American Society of Hematology, and the American Society of Clinical Oncology and he serves as an external reviewer for universities in Europe and the United States. Dr. Niederwieser is the author or co-author of numerous articles (<390) published in international peer-reviewed journals, such as The New England Journal of Medicine, Blood, the Journal of Clinical Oncology, the Journal of the American Medical Association, Nature Clinical Practice Oncology, Annals of Oncology, Leukemia, and Bone Marrow Transplantation.

Case Study


Barbara Melosky, MD, FRCP(C)

Dr. Barbara Melosky is a Clinical Associate Professor of Medicine at the University of British Columbia and a medical oncologist at the British Columbia Cancer Agency in Vancouver. She graduated from medical school at the University of Manitoba, and did a residency in internal medicine and an oncology fellowship at the University of British Columbia. Dr. Melosky is currently working in the fields of lung and gastrointestinal malignancies with a special interest in the side effects of targeted therapy. She sits on the Executive Committee for the Lung Disease Site NCIC Clinical Trials Group and is the annual Chair of the Canadian Lung Cancer Conference.

A Canadian Perspective on the Treatment of Unfit Patients with Chronic

Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults in the western world, accounting for approximately 11% of all hematological cancers. According to SEER (Surveillance Epidemiology and End Results)

More Papers

Case Study: First-line Treatment of a Patient with EGFR M+ Non-Small Cell Adenocarcinoma

Physician: Barbara Melosky, MD, FRCPC British Columbia Cancer Agency, Vancouver, British Columbia Presentation: 52-year-old Caucasian female. Cough for 4 months. Abnormal chest X-ray showed a right middle lobe mass of 8 cm.

More Papers

New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer

ASCO 2012

View Slides

Dr. Kuruvilla presents a summary of the Canadian follicular lymphoma guidelines

Watch Video